|
Mr. Lynch joined the Board in 2006. Mr. Lynch is the chairman, Chief Executive Officer and major shareholder of Amarin Corporation plc, an emerging biotech specialty pharmaceutical company, specializing in neurological diseases. He is also a non-executive director of ICON plc, a clinical research company; IDA Ireland (an agency of the Irish government responsible for inward investment); Neuronyx Inc., (a company specialising in stem cell research); and Tripep AB (a Swedish company conducting research in Aids/HIV and Hepatitis.). Mr Lynch was appointed to the board of IDA Ireland by the Irish government in December 2000 and was recently reappointed for a further five year term. The IDA is responsible for promoting Ireland as a location for inward investment; give grants and other support and state aid, and manage a substantial property portfolio. | 